Final Recommendation Statement
Cervical Cancer: Screening
August 21, 2018
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
|Women aged 21 to 65 years||The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. For women aged 30 to 65 years, the USPSTF recommends screening every 3 years with cervical cytology alone, every 5 years with high-risk human papillomavirus (hrHPV) testing alone, or every 5 years with hrHPV testing in combination with cytology (cotesting). See the Clinical Considerations section for the relative benefits and harms of alternative screening strategies for women 21 years or older.||A|
|Women younger than 21 years||The USPSTF recommends against screening for cervical cancer in women younger than 21 years.||D|
|Women who have had a hysterectomy||The USPSTF recommends against screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion (ie, cervical intraepithelial neoplasia [CIN] grade 2 or 3) or cervical cancer.||D|
|Women older than 65 years||The USPSTF recommends against screening for cervical cancer in women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer. See the Clinical Considerations section for discussion of adequate prior screening and risk factors that support screening after age 65 years.||D|
Clinician SummaryExpand All
|Population||Women aged 21 to 29 years||Women aged 30 to 65 years||Women younger than 21 years, women older than 65 years with adequate prior screening, and women who have had a hysterectomy|
|Recommendation||Screen for cervical cancer every 3 years with cytology alone.
|Screen for cervical cancer every 3 years with cytology alone, every 5 years with hrHPV testing alone, or every 5 years with cotesting.
|Do not screen for cervical cancer.
|Risk Assessment||All women aged 21 to 65 years are at risk for cervical cancer because of potential exposure to high-risk HPV types (hrHPV) through sexual intercourse and should be screened. Certain risk factors further increase risk for cervical cancer, including HIV infection, a compromised immune system, in utero exposure to diethylstilbestrol, and previous treatment of a high-grade precancerous lesion or cervical cancer. Women with these risk factors should receive individualized follow-up.|
|Screening Tests||Screening with cervical cytology alone, primary testing for hrHPV alone, or both at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer. Clinicians should focus on ensuring that women receive adequate screening, appropriate evaluation of abnormal results, and indicated treatment, regardless of which screening strategy is used.|
|Treatments and Interventions||High-grade cervical lesions may be treated with excisional and ablative therapies. Early-stage cervical cancer may be treated with surgery (hysterectomy) or chemotherapy.|
For a summary of the evidence systematically reviewed in making this recommendation, the full recommendation statement, and supporting documents, please go to http://www.uspreventiveservicestaskforce.org/.
- Screening for Cervical Cancer: AFP's Putting Prevention Into Practice - Educational Tools
Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients without obvious related signs or symptoms.
It bases its recommendations on the evidence of both the benefits and harms of the service and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment.
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.
The number of deaths from cervical cancer in the United States have decreased substantially since the implementation of widespread cervical cancer screening and continue to decline, from 2.8 per 100,000 women in 2000 to 2.3 deaths per 100,000 women in 2015.1 Most cases of cervical cancer occur among women who have not been adequately screened.2 Strategies that aim to ensure that all women are appropriately screened and receive adequate follow-up are most likely to succeed in further reducing cervical cancer incidence and mortality in the United States.
The USPSTF found convincing evidence that screening with cervical cytology alone, primary testing for high-risk HPV types (hrHPV testing) alone, or in combination at the same time (cotesting) can detect high-grade precancerous cervical lesions and cervical cancer.
The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone, every 5 years with hrHPV testing alone, or in combination in women aged 30 to 65 years outweigh the harms.
The USPSTF concludes with moderate certainty that the benefits of screening in women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer do not outweigh the potential harms.
The USPSTF concludes with moderate certainty that the harms of screening in women younger than 21 years outweigh the benefits.
The USPSTF concludes with high certainty that the harms of screening in women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer outweigh the benefits.
This recommendation statement applies to all asymptomatic individuals with a cervix, regardless of their sexual history. This recommendation statement does not apply to women who have been diagnosed with a high-grade precancerous cervical lesion or cervical cancer, women with in utero exposure to diethylstilbestrol, or women who have a compromised immune system (eg, women living with HIV).
Assessment of Risk
High-risk HPV infection is associated with nearly all cases of cervical cancer, and women are exposed to hrHPV through sexual intercourse. Although a large proportion of HPV infections resolve spontaneously, the high likelihood of exposure to hrHPV means that women are at risk for precancerous lesions and cervical cancer.
Certain risk factors increase risk for cervical cancer, including HIV infection, a compromised immune system, in utero exposure to diethylstilbestrol, and previous treatment of a high-grade precancerous lesion or cervical cancer. Women with these risk factors are not included in this recommendation and should receive individualized follow-up. Women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion or cervical cancer are not at risk for cervical cancer and should not be screened. As part of the clinical evaluation, clinicians should confirm through review of surgical records or direct examination that the cervix was removed.
Current evidence indicates that there are no clinically important differences between liquid-based cytology and conventional cytology. A variety of platforms are used to detect hrHPV; most use either signal or nucleic acid amplification methods. Published trials of hrHPV testing used in situ hybridization, polymerase chain reaction, and hybrid capture technology to test for HPV strains associated with cervical cancer. hrHPV testing has been used for primary screening, cotesting with cytology, and follow-up testing of positive cytology results (reflex hrHPV).2
Screening with cytology alone, hrHPV testing alone, and both in combination offer a reasonable balance between benefits and harms for women aged 30 to 65 years; women in this age group should discuss with their health care professional which testing strategy is best for them. Evidence from randomized clinical trials (RCTs) and decision modeling studies suggest that screening with cytology alone is slightly less sensitive for detecting CIN 2 and CIN 3 than screening with hrHPV testing alone. Although screening with hrHPV testing alone or in combination with cytology detects more cases of CIN 2 and CIN 3, this method results in more diagnostic colposcopies for each case detected.2-5
There are a number of different protocols for triage of abnormal results from screening with cytology, hrHPV testing, or cotesting. Clinical trial evidence and modeling suggest that different triage protocols have generally similar detection rates for CIN 2 and CIN 3; however, proceeding directly to diagnostic colposcopy without additional triage leads to a much greater number of colposcopies compared with using other triage protocols. Maintaining comparable benefits and harms of screening with cytology alone or hrHPV testing alone requires that patients, clinicians, and health care organizations adhere to currently recommended protocols for repeat testing, diagnostic colposcopy, and treatment.6,7
Timing of Screening
Women Younger Than 21 Years
Cervical cancer is rare before age 21 years.8 Exposure of cervical cells to hrHPV during vaginal intercourse may lead to cervical carcinogenesis, but the process has multiple steps, involves regression, and is generally not rapid. Because of the slow progression of disease and the high likelihood of regression in this age group, evidence suggests that screening earlier than age 21 years, regardless of sexual history, would lead to more harm than benefit. Treatment of CIN 2 or CIN 3 among women younger than 21 years may increase risk for adverse pregnancy outcomes.2,8
Women Older Than 65 Years
Joint guidelines from the American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology (ACS/ASCCP/ASCP) define adequate prior screening as 3 consecutive negative cytology results or 2 consecutive negative cotesting results within 10 years before stopping screening, with the most recent test occurring within 5 years.6 The guidelines further state that routine screening should continue for at least 20 years after spontaneous regression or appropriate management of a precancerous lesion, even if this extends screening past age 65 years. Once screening has stopped, it should not resume in women older than 65 years, even if they report having a new sexual partner.
Women Older Than 65 Years Who Have Not Been Adequately Screened
Screening may be clinically indicated in older women with an inadequate or unknown screening history. Recent data suggest that one-fourth of women aged 45 to 64 years have not been screened for cervical cancer in the preceding 3 years.9 In particular, women with limited access to care, women from racial/ethnic minority groups, and women from countries where screening is not available may be less likely to meet criteria for adequate prior screening. Certain considerations may also support screening in women older than 65 years who are otherwise at high risk (ie, women with a history of high-grade precancerous lesions or cervical cancer, in utero exposure to diethylstilbestrol, or a compromised immune system).2
Screening more frequently than every 3 years with cytology alone confers little additional benefit, with a large increase in harms, including additional procedures and assessment and treatment of transient lesions. Treatment of lesions that would otherwise resolve on their own is harmful because it can lead to procedures with unwanted adverse effects, including the potential for cervical incompetence and preterm labor during pregnancy. Evidence from RCTs, observational studies, and modeling studies suggest that a 5-year screening interval for primary hrHPV testing alone or cotesting offers the best balance of benefits and harms. Screening more frequently than every 5 years with primary hrHPV testing alone or cotesting does not substantially improve benefit but significantly increases the number of screening tests and colposcopies.
Screening aims to identify high-grade precancerous cervical lesions to prevent progression to cervical cancer. High-grade cervical lesions may be treated with excisional and ablative therapies. Early-stage cervical cancer may be treated with surgery (hysterectomy) or chemotherapy. Treatment of precancerous lesions is less invasive than treatment of cancer.2
Race/Ethnicity, Geography, and Cervical Cancer
The incidence of and mortality from cervical cancer remain relatively high among certain populations. The overall mortality rate from cervical cancer among African American women is 10.1 deaths per 100,000 women,10 which is more than twice the rate among white women (when adjusted for hysterectomy rate), although the gap has narrowed over time. Mortality is higher among older African American women. Several studies have found that African American women are screened for cervical cancer at rates similar to those for white women and that inadequate follow-up after screening and differences in treatment may be important contributing factors. The higher mortality rate in African American women may also be attributable, in part, to the higher than average rate of adenocarcinoma, which carries a worse prognosis than the most common type of cervical cancer (squamous cell carcinoma).10-12
American Indian/Alaska Native women also have higher rates of cervical cancer mortality (3.2 deaths per 100,000 women) than the US average.10 Factors driving this higher rate may include lower screening rates (16.5% of American Indian/Alaska Native women in the 2012 Behavioral Risk Factor Surveillance System reported not receiving a Papanicolaou [Pap] test in the past 5 years)13 and inadequate follow-up.2 Hispanic women have a significantly higher incidence rate of cervical cancer and slightly higher mortality rate (2.6 deaths per 100,000 women [unadjusted for hysterectomy rate]), with especially high rates occurring along the Texas-Mexico border. Although white women overall have the lowest mortality rate from cervical cancer, white women living in geographically isolated and medically underserved areas (particularly Appalachia) have much higher mortality rates than the US average. Asian women also have lower screening rates, especially those who have recently immigrated to the United States and may have language or cultural barriers to screening.10
In addition to race/ethnicity and geography, insurance coverage plays an important role in access to cervical cancer screening; 23.1% of women without health insurance and 25.5% of women with no regular health care clinician reported not receiving a Pap test in the past 5 years, compared with 11.4% of the general population. Insurance status may interact with other demographic factors, such as race/ethnicity and age, to increase disparities.13 In addition, there are no screening data for women with disabilities and those who identify as lesbian or transgender.14-16
Progress in reducing cervical cancer incidence and mortality has been uneven. The most important factors contributing to higher incidence and mortality rates include financial, geographic, and language or cultural barriers to screening; barriers to follow-up; unequal treatment; and difference in cancer types, all of which vary across subpopulations.
Additional Approaches to Prevention
The Centers for Disease Control and Prevention’s Advisory Council on Immunization Practice recommends routine HPV vaccination. A 2-dose schedule is recommended for girls and boys who initiate the vaccination series at ages 9 to 14 years. Three doses are recommended for girls and boys who initiate the vaccination series at ages 15 to 26 years and for those who have a compromised immune system.17 The overall effect of HPV vaccination on high-grade precancerous cervical lesions and cervical cancer is not yet known. Current trials have not yet provided data on long-term efficacy; therefore, the possibility that vaccination might reduce the need for screening with cytology or hrHPV testing is not established. Given these uncertainties, women who have been vaccinated should continue to be screened as recommended until further evidence accrues.
The Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America have issued recommendations on screening for and management of cervical cancer in patients living with HIV.18
The National Cancer Institute provides strategies for reducing cervical cancer mortality in its report “Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities.”19
Participation in regular screening has a far greater effect on cervical cancer morbidity and mortality than which of the 3 recommended screening strategies is chosen for women ages 30 to 65 years. Implementation should therefore focus on ensuring that women receive adequate screening, regardless of which strategy is used.
Although low screening rates contribute to high mortality rates in certain underserved populations, screening alone is not sufficient to reduce cervical cancer morbidity and mortality and related disparities. Loss to follow-up and disparities in treatment are also contributing factors. Therefore, having systems in place to ensure follow-up of abnormal results, appropriate treatment of any pathology, and support to retain patients throughout the entirety of cancer treatment are important.
Research Needs and Gaps
Regular screening for prevention of cervical cancer is highly effective, whether it is with cervical cytology alone, hrHPV testing alone, or both in combination. To further reduce the incidence and mortality of cervical cancer, it is necessary to find effective strategies to reach inadequately screened and unscreened women and to address follow-up and treatment issues.
Research is needed to evaluate whether different screening strategies could play a part in reducing mortality rates, as well as ways to improve follow-up for current screening strategies and to ensure equitable access to treatment across populations. In addition, research is needed to determine whether screening after age 65 years has a different balance of benefits and harms in different subpopulations.
Unlike cytology, samples for hrHPV testing have the potential to be collected by the patient and mailed to health programs for analysis, meaning self-collection may be one strategy for increasing screening rates among populations where they are currently low. Rigorous comparative studies are needed to verify this hypothesis and to identify effective strategies for implementation.
Another important area for future research is the effect of HPV vaccination, because an increasing number of women and men of screening age are being vaccinated. Decreases in hrHPV type prevalence due to vaccination could reduce the positive predictive value of hrHPV testing, which, along with potential reductions in cancer incidence, may increase the number of false-positive results and, therefore, the balance of benefits and harms. In either case, screening strategies may need to be adjusted.
Burden of Disease
Cervical cancer incidence and mortality have decreased significantly since the 1960s because of widespread screening.2 In 2018, an estimated 13,240 new cases and 4,170 deaths will occur, making cervical cancer the 18th most common cause of cancer death in the United States.20 Most cases of cervical cancer and related deaths occur among women who have not been adequately screened, followed up, or treated.2 In 2013, 81.7% of women aged 21 to 44 years and 79.2% of women aged 45 to 64 years reported receiving a Pap test in the past 3 years, as recommended.9 While this is a much higher coverage rate than that of many other cancer screening programs, it still falls short of the Healthy People 2020 goal of screening 93% of women aged 21 to 65 years.21 Further, the burden of cervical cancer incidence and mortality falls disproportionately on racial/ethnic and sexual/gender minority groups, persons with disabilities, and low-income and geographically defined populations.10
Scope of Review
The USPSTF commissioned a review of the evidence2,4 on screening for cervical cancer to update its 2012 recommendation.22 The review focused on outcomes from trials and cohort studies in high-resource countries that evaluated screening with hrHPV testing alone or hrHPV and cytology together (cotesting) compared with cervical cytology alone. The review did not examine data on test accuracy or the effectiveness of cytology for screening for cervical cancer, as both were established in the previous evidence review.23 Similarly, the review did not systematically examine data for women younger than 21 years or for women who have had a hysterectomy with removal of the cervix except to confirm that the evidence has not changed since the previous review.
In addition to the systematic evidence review, the USPSTF commissioned a decision analysis model3,5 to evaluate the age at which to begin and end screening, the optimal interval for screening, the effectiveness of different screening strategies, and how these factors affect the relative benefits and harms of different screening strategies. The USPSTF approach to the use of model-based analysis as a complement to systematic evidence reviews is described in detail elsewhere.24
Accuracy of Screening Tests
Evidence from RCTs indicates that hrHPV testing and cotesting can detect more cases of CIN 3, but they also have higher false-positive rates compared with cytology alone. Cotesting has the highest false-positive rate. False-positive rates are also higher among women younger than 30 years than among older women because of the higher incidence of transient HPV infection in younger women, even though cervical cancer incidence is lower in this age group.2
Estimates of sensitivity and specificity of any screening strategy are heavily influenced by the follow-up of abnormal results, and follow-up protocols in cervical cancer screening trials varied widely.2
Effectiveness of Different Screening Strategies
The reduction of mortality and morbidity associated with the introduction of cytology-based screening is consistent across populations. A cluster RCT conducted in India found a nearly 50% reduction in cervical cancer mortality after a single round of hrHPV testing compared with a nonscreened control group after 8 years of follow-up.25 The evidence review did not address whether screening for cervical cancer is effective but rather which screening strategies are most effective, when to start screening, and when to stop screening.
Women Younger Than 21 Years
The USPSTF considered the following types of evidence to determine when screening for cervical cancer should begin: cervical cancer incidence, prevalence, and mortality among young women; the natural history of precancerous lesions and HPV infection; and the effects of screening in populations of young women. Cervical cancer is rare among women younger than 20 years; according to US Surveillance, Epidemiology, and End Results data, 0.1% of all incident cancer cases occur in this age group.1 Precancerous lesions are also uncommon. Estimated prevalence of CIN 3 among women younger than 20 years is 0.2%, with a concurrent false-positive cytology rate of about 3.1%.26 In addition, the decision analysis model commissioned for the 2012 USPSTF recommendation showed no net benefit to starting screening before age 21 years.27 The USPSTF did not look at evidence for women younger than 21 years living with HIV or who are otherwise at higher risk of cervical cancer, as they are outside the scope of this recommendation.
Women Aged 21 to 29 Years
The USPSTF recommends screening for cervical cancer every 3 years with cervical cytology alone in women aged 21 to 29 years. Given the high prevalence of transient HPV infection among adolescents and young adults, initial screening at age 21 years should be with cytology alone. The question of what age at which screening with hrHPV testing alone offers comparable benefit has not been directly studied. The 4 trials that compared screening with hrHPV testing alone vs cytology alone found a consistently higher detection rate among younger women (younger than 30 or 35 years), which raises concern for overdiagnosis and overtreatment of transient infection.28-31 Modeling estimates of the effects of switching from screening with cytology alone to hrHPV testing alone at ages 25, 27, and 30 years found minimal differences in terms of life-years gained compared with switching screening strategies at age 30 vs 25 years (64,193 vs 64,195 life-years gained per 1000 women screened, respectively). However, screening with hrHPV testing alone starting at age 25 years rather than age 30 years increased the number of colposcopies by nearly 400 colposcopies per 1000 women screened.3 Therefore, switching from cytology alone to hrHPV testing alone at age 30 years appears to offer similar benefits in terms of cancer reduction as switching at younger ages but with fewer associated tests and procedures.
Women Aged 30 to 65 Years
The USPSTF found 8 trials of cervical cancer screening; 4 RCTs compared screening with hrHPV testing alone vs cytology alone and 4 RCTs compared screening with cytology alone vs cotesting (cytology in combination with hrHPV testing).2 No trials directly compared screening strategies using hrHPV testing alone vs cotesting. Meta-analysis was not possible because the trials varied substantially in terms of cytology type (conventional vs liquid-based), hrHPV test (polymerase chain reaction vs hybrid capture), screening interval (2 to 5 years), follow-up protocols for abnormal results, and protocols for screening beyond the first round. No trial included more than 2 rounds of screening. Although the purpose of screening is to reduce cervical cancer mortality, the mortality rate is so low in countries that have organized cytology screening programs that it is impractical to directly measure the effects of different screening strategies on mortality through clinical trials. Therefore, trials measured the rate of CIN 3+ (CIN 3 or worse) detection, and some trials also reported the rate of invasive cervical cancer.
hrHPV Testing Alone vs Conventional Cytology Alone
Four RCTs (N > 250,000 women) compared screening with hrHPV testing alone vs cytology alone: the New Technologies for Cervical Cancer (NTCC) Phase II trial in Italy,28,32-34 the HPV for Cervical Cancer Screening (HPV FOCAL) trial in Canada,29 the FINNISH trial in Finland,30 and the Compass trial in Australia.31 Overall, the 4 trials found that hrHPV testing alone led to an increase in the rate of CIN 3+ detection compared with cytology alone in the first round of screening. The NTCC Phase II and HPV FOCAL trials enrolled women aged 25 to 60 or 65 years and had 2 rounds of screening 2 to 4 years apart. The FINNISH trial, which enrolled women aged 25 to 65 years, had a single round of screening and then followed up participants for 5 years through a cancer registry. The Compass trial, which enrolled 4995 women aged 25 to 64 years, randomized participants to liquid-based cytology every 2.5 years or hrHPV primary screening every 5 years.
The NTCC Phase II trial found that hrHPV testing alone had a cumulative CIN 3+ detection rate twice that of cytology alone (0.4% vs 0.2%). The FINNISH trial measured the rate of invasive cervical cancer detection at 5 years; screening with hrHPV testing alone had a detection rate of 0.03% and screening with cytology alone had a detection rate of 0.01%. Recently published results from the HPV FOCAL trial35 found that hrHPV testing alone had a higher detection rate for CIN 3+ (0.7%) compared with cytology (0.4%) after 4 years of follow-up. The Compass trial reported preliminary results consistent with those from the other 3 trials, but final results at 5 years of follow-up have not yet been published.
The primary harms measured in the RCTs were the total number of follow-up tests, number of colposcopies, and false-positive rates. Although follow-up tests and colposcopies are essential to detection of cancer, they represent a burden and risk to patients and are a proxy measure for downstream harms; therefore, screening strategies that minimize the number of tests and colposcopies per each cancer case averted are desirable. Colposcopy rates were higher for hrHPV testing alone than for cytology alone in 1 of 3 trials (NTCC Phase II) and similar in 2 trials (FINNISH and HPV FOCAL). False-positive rates for CIN 2+ were higher for hrHPV testing alone than for cytology alone in 1 trial (NTCC Phase II) and similar in another trial (FINNISH).
Cotesting vs Cytology Alone
Four RCTs (N > 130,000 women) compared screening with cytology alone vs cotesting (cytology in combination with hrHPV testing): the NTCC Phase I trial in Italy,28,32,34 Swedescreen in Sweden,36,37 A Randomized Trial in Screening to Improve Cytology (ARTISTIC) in the United Kingdom,38-40 and the Population-Based Screening Study Amsterdam (POBASCAM) in the Netherlands.41 In all 4 trials, the cumulative relative ratio of CIN 3+ detection between the 2 strategies (cotesting vs cytology alone) were not statistically significant after 2 rounds of screening. The trials varied considerably in starting age (20 to 29 years), stopping age (38 to 64 years), and follow-up protocols. The NTCC Phase I, ARTISTIC, and POBASCAM trials reported 2 rounds of screening at 3- to 5-year intervals, whereas Swedescreen reported 1 round of screening with registry follow-up at 3 years. Two trials (Swedescreen and POBASCAM) reported no difference between screening strategies at 13 to 14 years of follow-up.
These 4 trials reported hrHPV positive rates of 7% to 22% for screening with cotesting; again, rates were highest among women younger than 30 or 35 years. Colposcopy rates were higher for screening with cotesting than for cytology alone in 2 trials (ARTISTIC and NTCC Phase I) and not reported in the other 2 trials (Swedescreen and POBASCAM). False-positive rates were higher for screening with cotesting in 3 of 4 trials (Swedescreen did not report the false-positive rate for the intervention group).
The ARTISTIC trial also surveyed a subsample of patients (N = 2508) about the psychological effects of screening.42 It found no difference in distress or anxiety between women screened with cotesting and women screened with cytology alone. Women in the cotesting group who were notified of positive HPV results reported lower sexual satisfaction regardless of their cytology results, but there were no statistically significant differences in psychological distress or anxiety between study groups.38 A separate cross-sectional study used a survey to evaluate the psychological effects of screening with hrHPV cotesting in women aged 20 to 64 years (N = 428) and found that women who received a positive HPV result were more distressed and had more negative feelings about their sexual partners than women who received a negative HPV result.43
Additional Evidence From Observational Studies
In addition to RCTs, the USPSTF also reviewed evidence from an individual participant data meta-analysis that pooled patients from 4 trials (NTCC Phase I, Swedescreen, ARTISTIC, and POBASCAM), as well as a single trial of primary hrHPV testing (NTCC Phase II). The meta-analysis found a 40% lower incidence of invasive cervical cancer among patients screened with some form of hrHPV testing compared with cytology alone.44 Biopsy rates from the individual participant data meta-analysis suggest that these higher colposcopy rates led to higher rates of biopsy with cotesting than with cytology alone. However, since the meta-analysis pooled data from trials with distinctly different screening strategies and hrHPV test types, these findings cannot be interpreted with certainty.
The trial evidence was also supplemented with results from 4 cohort studies. One study considered primary hrHPV screening,45 2 studies considered cotesting,46-51 and 1 reported on cotesting among underscreened women.52 These outcomes were not notably different from the trial outcomes. A recently published report on women (N = 1,262,713) screened 1 or more times in Kaiser Permanente Northern California between 2003 and 2015, which included women aged 25 to 29 years screened with cytology and triage with hrHPV testing for atypical squamous cells of undetermined significance and women aged 30 to 77 years screened with cotesting, also suggests that women who test negative for hrHPV have very low rates of subsequent CIN 3+, regardless of cytology results.53 It is important to note that women younger than 30 or 35 years had higher hrHPV-positive and CIN 3+ rates, accompanied by higher colposcopy rates.
Data from long-term follow-up studies37,54 and a large US cohort study55 suggest a minimal risk of missing cervical cancer among women who test negative with cotesting or primary hrHPV screening. An analysis of long-term data from Kaiser Permanente Northern California suggests that women with 1 or more negative results from cotesting have a reduced risk for future cancer.53
Benefits and Harms of Various Screening Strategies Based on Decision Modeling
The decision model commissioned by the USPSTF reported benefits and harms consistent with the outcomes observed in the trials. Both hrHPV testing alone and cotesting would avert approximately 1 additional cancer case per 1000 women screened compared with cytology alone (17.8 vs 16.5 cases, respectively), representing a very small improvement in life-years gained (64,193 vs 64,182 life-years, respectively).3 However, these 2 screening strategies would also subject women to more tests and procedures. Although no head-to-head trials compared screening with hrHPV testing alone vs cotesting, modeling suggests that both hrHPV testing alone and cotesting offer similar benefit over cytology in terms of cancer cases averted and are also similar in terms of the number of colposcopies required (1630 vs 1635, respectively). In summary, all 3 screening strategies offer substantial benefit in terms of reducing cancer incidence and mortality compared with no screening.
Screening Interval Based on Decision Modeling
The decision model conducted for the 2012 USPSTF recommendation found that screening every 3 years with cytology alone starting at age 21 years confers a similar number of life-years gained as annual screening (69,?247 vs 69,213 life-years gained per 1000 women screened, respectively), yet results in fewer than half the number of colposcopies and fewer false-positive results.27 Screening intervals for hrHPV testing varied across trials from 2 to 5 years, and observational studies of primary hrHPV testing and cotesting examined intervals from 3 to 5 years. For women aged 30 to 65 years, modeling suggests similar life-years gained with 3- and 5-year screening intervals but more tests and procedures with a 3-year screening interval (64,193.19 vs 64,193.07 life-years gained per 1000 women screened every 3 and 5 years, respectively).3 Thus, the USPSTF recommends 5-year screening intervals for hrHPV testing alone or for cotesting based on evidence from RCTs, observational data, and modeling studies (Table).
Women Older Than 65 Years
None of the screening trials enrolled women older than 65 years, so direct evidence on when to stop screening is not available. When deliberating on the age at which to stop screening, the USPSTF considered the incidence of cervical cancer in older women and whether the pattern of cervical cancer incidence differs in screened vs unscreened women. The incidence and prevalence of CIN peak in the midreproductive years and begin to decline in approximately the fourth decade of life, a general pattern also apparent among certain previously unscreened women. Cervical cancer in older women is not more aggressive or rapidly progressive than it is in younger women. The rate of high-grade squamous intraepithelial lesions diagnosed by cytology is low in older women who have had adequate prior screening. The decision model commissioned by the USPSTF also supports the current practice of stopping screening at age 65 years in adequately screened women. The model projected that extending screening beyond age 65 years in women with an adequate screening history would not have significant benefit using any of the considered screening strategies.
Although screening women older than 65 years who have an adequate screening history is not recommended, data suggest that screening rates begin to decline before that age. As a result, approximately 13% of 65-year-old women have not been adequately screened, and this number increases to 37.1% if the patient has no regular health care provider.13 A Kaiser Permanente registry study found that the majority of cases of invasive cervical cancer among women older than 65 years occurred among those who had not met criteria for stopping screening.55,62 This suggests that the decision to stop screening at age 65 years should only be made after confirming that the patient has received prior adequate screening. Current guidelines define adequate screening as 3 consecutive negative cytology results or 2 consecutive negative HPV results within 10 years before stopping screening, with the most recent test performed within 5 years.6
Women Who Have Had a Hysterectomy With Removal of the Cervix
Two large studies have documented the low risk for cytology abnormalities after hysterectomy. A cross-sectional study of more than 5000 cytology tests among women older than 50 years found that identification of vaginal intraepithelial neoplasia and cancer was rare in this age group after hysterectomy.63 In a second study of more than 10,000 Pap tests performed over 2 years in 6265 women who had a hysterectomy with removal of the cervix, screening yielded 104 abnormal Pap test results and no cases of cervical cancer; in addition, 6 cases of high-grade vaginal lesions were detected, but it is not known whether detection of these cases improved clinical outcomes.64
Harms of Screening
Screening with cervical cytology and hrHPV testing can lead to harms, including more frequent follow-up testing and invasive diagnostic procedures (eg, colposcopy and cervical biopsy), as well as unnecessary treatment in women with false-positive results. Evidence from RCTs and observational studies indicate that harms from diagnostic procedures include vaginal bleeding, pain, infection, and failure to diagnose (due to inadequate sampling). Abnormal screening test results are also associated with psychological harms. In particular, women who received positive hrHPV results reported greater distress and lower satisfaction with past and current sexual partners than women who received abnormal cytology results.
The USPSTF found adequate evidence that the harms of hrHPV testing alone in women aged 21 to 29 years are moderate. Primary hrHPV testing has been found to result in high rates of positive tests in this age group, in which HPV infections are likely to resolve spontaneously. The high frequency of transient HPV infection among women younger than 30 years can lead to unnecessary follow-up diagnostic and treatment interventions with potential for harm.
The USPSTF found adequate evidence that the harms of screening for cervical cancer (with cytology alone, hrHPV testing alone, or cotesting with both) in women aged 30 to 65 years are moderate. Screening strategies that include hrHPV testing are slightly more sensitive than those that include cytology alone but also yield more false-positive results. Cotesting is also slightly more sensitive than cytology alone but leads to the highest false-positive rates.
The USPSTF found adequate evidence that the harms of screening for cervical cancer in women older than 65 years who have had adequate prior screening and are not otherwise at high risk are at least small. The USPSTF also found adequate evidence that the harms of screening for cervical cancer in women younger than 21 years are moderate.
The USPSTF found adequate evidence that screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion or cervical cancer is associated with harms.
Harms of Treatment
The harms of treatment include risks from the treatment procedure and the potential subsequent consequences of treatment. Evidence from observational studies indicates that certain treatments for precancerous lesions (eg, cold-knife conization and loop excision) are associated with subsequent adverse pregnancy outcomes, such as preterm delivery and related complications.2 The USPSTF found convincing evidence that many precancerous cervical lesions will regress and that other lesions are indolent, slow growing, and will not become clinically important over a woman’s lifetime; identification and treatment of these lesions constitute overdiagnosis. Estimating the precise magnitude of overdiagnosis associated with any screening or treatment strategy is difficult, but it is of concern because it confers no benefit and leads to unnecessary surveillance, diagnostic tests, and treatments, with associated harms.
Estimate of Magnitude of Net Benefit
There is convincing evidence that screening with cervical cytology alone, primary hrHPV testing alone, or cotesting can detect high-grade precancerous cervical lesions and cervical cancer. The USPSTF found convincing evidence that screening women aged 21 to 65 years substantially reduces cervical cancer incidence and mortality. The USPSTF found adequate evidence that the harms of screening for cervical cancer (with cytology alone, hrHPV testing alone, or cotesting with both) in women aged 30 to 65 years are moderate. The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone in women aged 21 to 29 years substantially outweigh the harms. The USPSTF concludes with high certainty that the benefits of screening every 3 years with cytology alone, every 5 years with hrHPV testing alone, or every 5 years with both in combination in women aged 30 to 65 years outweigh the harms.
The USPSTF found adequate evidence that screening women older than 65 years who have had adequate prior screening and women younger than 21 years does not provide significant benefit. There is convincing evidence that screening women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer provides no benefit. The USPSTF found adequate evidence that the harms of screening for cervical cancer in women younger than 21 years and of screening with hrHPV testing alone in women aged 21 to 29 years are moderate. The USPSTF found adequate evidence that the harms of screening for cervical cancer in women older than 65 years who have had adequate prior screening and are not otherwise at high risk are at least small. The USPSTF found adequate evidence that screening for cervical cancer in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion or cervical cancer is associated with harms. The USPSTF concludes with moderate to high certainty that screening women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer, screening women younger than 21 years, and screening women who have had a hysterectomy with removal of the cervix for indications other than a high-grade precancerous lesion or cervical cancer does not result in a positive net benefit.
How Does Evidence Fit With Biological Understanding?
The natural history of cervical cancer has been well studied. Infection of the cervix with HPV is generally transient, but when the infection is not cleared by an appropriate immune response and the virus is of an oncogenic type, the infection can result in incorporation of HPV gene sequences into the host genome, which can lead to precancerous lesions. The long preclinical phase from infection to development of precancerous lesions and cervical cancer allows for the opportunity to effectively screen for, identify, and treat precancerous lesions, thereby reducing cervical cancer incidence and mortality.
Response to Public Comment
A draft version of this recommendation statement was posted for public comment on the USPSTF website from September 12, 2017, through October 13, 2017. Many comments pointed to a need for greater clarity in describing differences between cotesting and primary hrHPV testing. Several comments requested clarification on the information presented in the modeling report. Some comments highlighted implementation issues due to a lack of tests approved by the US Food and Drug Administration for primary cervical cancer screening. In response to these comments, the USPSTF now notes throughout the recommendation statement that women aged 30 to 65 years may choose to get screened every 3 years with cervical cytology alone, every 5 years with hrHPV testing alone, or every 5 years with cotesting. Accordingly, the USPSTF provided a table in the Clinical Considerations section that presents detailed information about the available evidence on the effectiveness, strengths, limitations, and unique considerations of each screening method. For further clarification on the modeling study, the USPSTF added the calibrated input parameter values, which should enable informed readers to assess the estimates used. The USPSTF added language throughout the recommendation statement to emphasize the importance of several different factors that affect overall screening effectiveness, including the primary screening test, screening ages, screening interval, test characteristics, and follow-up protocols, including triage of screen-positive women.
This recommendation replaces the 2012 USPSTF recommendation. The major change in the current recommendation is that the USPSTF now recommends screening every 5 years with hrHPV testing alone as an alternative to screening every 3 years with cytology alone among women aged 30 to 65 years. These are the 2 preferred screening strategies based on the USPSTF review of trial, cohort, and modeling results. Cotesting as an alternative strategy has demonstrated similar effectiveness, although it may result in more tests and procedures compared with either cytology or hrHPV testing alone. As in the 2012 recommendation, the USPSTF continues to recommend against screening in women younger than 21 years, in women older than 65 years who have had adequate prior screening and are not otherwise at high risk for cervical cancer, and in women who have had a hysterectomy with removal of the cervix and do not have a history of a high-grade precancerous lesion or cervical cancer.
The ACS/ASCCP/ASCP recommend that women aged 21 to 29 years be screened every 3 years with cytology alone (cervical cytology or Pap testing). Women aged 30 to 65 years should be screened every 5 years with cytology and HPV testing (cotesting) or every 3 years with cytology alone. Women at increased risk of cervical cancer (ie, women with a history of cervical cancer, a compromised immune system, or diethylstilbestrol exposure) may need to be screened more often. Women who have had CIN 2+ should continue screening for 20 years after the last abnormal test result, even if it extends screening beyond age 65 years.6 The ASCCP and SGO issued interim guidance in 2015 that recommended primary HPV screening starting at age 25 years as an alternative to cytology alone or cotesting.7 The American Academy of Family Physicians guidelines are in agreement with the USPSTF.65 The American College of Obstetricians and Gynecologists stated in 2016 that cytology alone and cotesting are still specifically recommended in current guidelines from most major societies; however, primary HPV screening in women 25 years or older can be considered as an alternative to current cytology-based screening if performed per ASCCP and SGO interim guidance.66 The Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents has issued guidance on screening for and management of HPV in patients living with HIV.18
The US Preventive Services Task Force (USPSTF) members include the following individuals: Susan J. Curry, PhD (University of Iowa, Iowa City); Alex H. Krist, MD, MPH (Fairfax Family Practice Residency, Fairfax, Virginia, and Virginia Commonwealth University, Richmond); Douglas K. Owens, MD, MS (Veterans Affairs Palo Alto Health Care System, Palo Alto, California, and Stanford University, Stanford, California); Michael J. Barry, MD (Harvard Medical School, Boston, Massachusetts); Aaron B. Caughey, MD, PhD (Oregon Health & Science University, Portland); Karina W. Davidson, PhD, MASc (Columbia University, New York, New York); Chyke A. Doubeni, MD, MPH (University of Pennsylvania, Philadelphia); John W. Epling Jr, MD, MSEd (Virginia Tech Carilion School of Medicine, Roanoke); Alex R. Kemper, MD, MPH, MS (Nationwide Children’s Hospital, Columbus, Ohio); Martha Kubik, PhD, RN (Temple University, Philadelphia, Pennsylvania); C. Seth Landefeld, MD (University of Alabama at Birmingham); Carol M. Mangione, MD, MSPH (University of California, Los Angeles); Maureen G. Phipps, MD, MPH (Brown University, Providence, Rhode Island); Michael Silverstein, MD, MPH (Boston University, Boston, Massachusetts); Melissa A. Simon, MD, MPH (Northwestern University, Evanston, Illinois); Chien-Wen Tseng, MD, MPH, MSEE (University of Hawaii, Honolulu, and Pacific Health Research and Education Institute, Honolulu, Hawaii); John B. Wong, MD (Tufts University School of Medicine, Boston, Massachusetts).
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Authors followed the policy regarding conflicts of interest described at https://www.uspreventiveservicestaskforce.org/Page/Name/conflict-of-interest-disclosures. All members of the USPSTF receive travel reimbursement and an honorarium for participating in USPSTF meetings. Dr Barry reported serving as chief science officer of Healthwise. Dr Epling reported serving as a statewide presenter for a National Area Health Education Center Organization grant from the Centers for Disease Control and Prevention to promote human papillomavirus (HPV) vaccine use among primary care physicians. Dr Simon reported receiving a grant from the Merck Foundation related to the topic of cervical cancer (Merck & Co is the maker of the GARDASIL vaccine for HPV). No other authors reported disclosures.
Funding/Support: The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF.
Disclaimer: Recommendations made by the USPSTF are independent of the US government. They should not be construed as an official position of AHRQ or the US Department of Health and Human Services.
Copyright Notice: USPSTF recommendations are based on a rigorous review of existing peer-reviewed evidence and are intended to help primary care clinicians and patients decide together whether a preventive service is right for a patient's needs. To encourage widespread discussion, consideration, adoption, and implementation of USPSTF recommendations, AHRQ permits members of the public to reproduce, redistribute, publicly display, and incorporate USPSTF work into other materials provided that it is reproduced without any changes to the work of portions thereof, except as permitted as fair use under the US Copyright Act.
AHRQ and the US Department of Health and Human Services cannot endorse, or appear to endorse, derivative or excerpted materials, and they cannot be held liable for the content or use of adapted products that are incorporated on other Web sites. Any adaptations of these electronic documents and resources must include a disclaimer to this effect. Advertising or implied endorsement for any commercial products or services is strictly prohibited.
This work may not be reproduced, reprinted, or redistributed for a fee, nor may the work be sold for profit or incorporated into a profit-making venture without the express written permission of AHRQ. This work is subject to the restrictions of Section 1140 of the Social Security Act, 42 U.S.C. §320b-10. When parts of a recommendation statement are used or quoted, the USPSTF Web page should be cited as the source.
1. National Cancer Institute (NCI). Cancer Stat Facts: cervical cancer. NCI website. https://seer.cancer.gov/statfacts/html/cervix.html. Accessed June 28, 2018.
2. Melnikow J, Henderson JT, Burda BU, et al. Screening for Cervical Cancer With High-Risk Human Papillomavirus Testing: A Systematic Evidence Review for the US Preventive Services Task Force. Evidence Synthesis No. 158. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 15-05224-EF-1.
3. Kim JJ, Burger EA, Regan C, Sy S. Screening for Cervical Cancer in Primary Care: A Decision Analysis for the US Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2018. AHRQ publication 15-05224-EF-2.
4. Melnikow J, Henderson JT, Burda BU, Senger CA, Durbin S, Weyrich MS. Screening for cervical cancer with high-risk human papillomavirus testing: updated evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2018;320(7):687-705.
5. Kim JJ, Burger EA, Regan C, Sy S. Screening for cervical cancer in primary care: a decision analysis for the US Preventive Services Task Force. JAMA. 2018;320(7):706-714.
6. Saslow D, Solomon D, Lawson HW, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. J Low Genit Tract Dis. 2012;16(3):175-204.
7. Huh WK, Ault KA, Chelmow D, et al. Use of primary high-risk human papillomavirus testing for cervical cancer screening: interim clinical guidance. Obstet Gynecol. 2015;125(2):330-7.
8. Benard VB, Watson M, Castle PE, Saraiya M. Cervical carcinoma rates among young females in the United States. Obstet Gynecol. 2012;120(5):1117-23.
9. National Center for Health Statistics. Health, United States, 2015: With Special Feature on Racial and Ethnic Health Disparities. Hyattsville, MD: National Center for Health Statistics; 2016. Report 2016-1232.
10. Beavis AL, Gravitt PE, Rositch AF. Hysterectomy-corrected cervical cancer mortality rates reveal a larger racial disparity in the United States. Cancer. 2017;123(6):1044-50.
11. Wang SS, Sherman ME, Hildesheim A, Lacey JV Jr, Devesa S. Cervical adenocarcinoma and squamous cell carcinoma incidence trends among white women and black women in the United States for 1976-2000. Cancer. 2004;100(5):1035-44.
12. Galic V, Herzog TJ, Lewin SN, et al. Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol. 2012;125(2):287-91.
13. Benard VB, Thomas CC, King J, Massetti GM, Doria-Rose VP, Saraiya M; Centers for Disease Control and Prevention (CDC). Vital signs: cervical cancer incidence, mortality, and screening--United States, 2007-2012. MMWR Morb Mortal Wkly Rep. 2014;63(44):1004-9.
14. Andresen EM, Peterson-Besse JJ, Krahn GL, Walsh ES, Horner-Johnson W, Iezzoni LI. Pap, mammography, and clinical breast examination screening among women with disabilities: a systematic review. Womens Health Issues. 2013;23(4):e205-14.
15. Tracy JK, Schluterman NH, Greenberg DR. Understanding cervical cancer screening among lesbians: a national survey. BMC Public Health. 2013;13:442.
16. Peitzmeier SM, Reisner SL, Harigopal P, Potter J. Female-to-male patients have high prevalence of unsatisfactory Paps compared to non-transgender females: implications for cervical cancer screening. J Gen Intern Med. 2014;29(5):778-84.
17. Advisory Committee for Immunization Practices (ACIP), Centers for Disease Control and Prevention (CDC). Human papillomavirus (HPV) ACIP vaccine recommendations. CDC website. https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/hpv.html. Accessed June 28, 2018.
18. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: human papillomavirus disease. National Institutes of Health website. https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-oi-prevention-and-treatment-guidelines/343/hpv. Accessed June 28, 2018.
19. Freeman HP, Wingrove BK. Excess Cervical Cancer Mortality: A Marker for Low Access to Health Care in Poor Communities. Rockville, MD: National Cancer Institute, Center to Reduce Cancer Health Disparities; 2005. NIH publication 05-5282.
20. American Cancer Society (ACS). Cervix at a glance. ACS website. https://cancerstatisticscenter.cancer.org/#!/cancer-site/Cervix. Accessed June 28, 2018.
21. Healthy People 2020. Cancer objectives. HealthyPeople.gov website. https://www.healthypeople.gov/2020/topics-objectives/topic/cancer/objectives. Updated June 18, 2018. Accessed June 28, 2018.
22. U.S. Preventive Services Task Force. Screening for cervical cancer: U.S. Preventive Services Task Force recommendation statement [published correction appears in Ann Intern Med. 2013;158(11):852]. Ann Intern Med. 2012;156(12):880-891, W312.
23. Vesco KK, Whitlock EP, Eder M, et al. Screening for Cervical Cancer: A Systematic Evidence Review for the US Preventive Services Task Force: Evidence Synthesis No. 86. Rockville, MD: Agency for Healthcare Research and Quality; 2011. AHRQ publication 11-05156-EF-1.
24. Owens DK, Whitlock EP, Henderson J, et al; U.S. Preventive Services Task Force. Use of decision models in the development of evidence-based clinical preventive services recommendations: methods of the U.S. Preventive Services Task Force. Ann Intern Med. 2016;165(7):501-8.
25. Sankaranarayanan R, Nene BM, Shastri SS, et al. HPV screening for cervical cancer in rural India. N Engl J Med. 2009;360(14):1385-94.
26. Insinga RP, Glass AG, Rush BB. Diagnoses and outcomes in cervical cancer screening: a population-based study. Am J Obstet Gynecol. 2004;191(1):105-13.
27. Kulasingam SL, Havrilesky L, Ghebre R, Myers ER. Screening for Cervical Cancer: A Decision Analysis for the U.S. Preventive Services Task Force. AHRQ Publication No 11-05157-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; 2011.
28. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening (NTCC) Working Group. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial. Lancet Oncol. 2010;11(3):249-57.
29. Ogilvie G, Krajden M, van Niekerk D, et al. HPV for cervical cancer screening (HPV FOCAL): complete round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer. Int J Cancer. 2017;140(2):440-8.
30. Leinonen MK, Nieminen P, Lönnberg S, et al. Detection rates of precancerous and cancerous cervical lesions within one screening round of primary human papillomavirus DNA testing: prospective randomised trial in Finland. BMJ. 2012;345:e7789.
31. Canfell K, Caruana M, Gebski V, et al. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: results of the Compass pilot randomised trial. PLoS Med. 2017;14(9):e1002388
32. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol. 2006;7(7):547-555.
33. Ronco G, Segnan N, Giorgi-Rossi P, et al; New Technologies for Cervical Cancer Working Group. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial. J Natl Cancer Inst. 2006;98(11):765-774.
34. Ronco G, Giorgi-Rossi P, Carozzi F, et al; New Technologies for Cervical Cancer Screening Working Group. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst. 2008;100(7):492-501.
35. Ogilvie GS, van Niekerk D, Krajden M, et al. Effect of screening with primary cervical HPV testing vs cytology testing on high-grade cervical intraepithelial neoplasia at 48 months: the HPV FOCAL randomized clinical trial. JAMA. 2018;320(1):43-52.
36. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med. 2007;357(16):1589-97.
37. Elfström KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ. 2014;348:g130.
38. Kitchener HC, Fletcher I, Roberts C, Wheeler P, Almonte M, Maguire P. The psychosocial impact of human papillomavirus testing in primary cervical screening--a study within a randomized trial. Int J Gynecol Cancer. 2008;18(4):743-8.
39. Kitchener HC, Almonte M, Gilham C, et al; ARTISTIC Trial Study Group. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess. 2009;13(51):1-150, iii-iv.
40. Kitchener HC, Almonte M, Thomson C, et al. HPV testing in combination with liquid-based cytology in primary cervical screening (ARTISTIC): a randomised controlled trial. Lancet Oncol. 2009;10(7):672-82.
41. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol. 2012;13(1):78-88.
42. Kitchener HC, Canfell K, Gilham C, et al. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds. Health Technol Assess. 2014;18(22):1-196.
43. McCaffery K, Waller J, Forrest S, Cadman L, Szarewski A, Wardle J. Testing positive for human papillomavirus in routine cervical screening: examination of psychosocial impact. BJOG. 2004;111(12):1437-43.
44. Ronco G, Dillner J, Elfström KM, et al; International HPV Screening Working Group. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014;383(9916):524-532.
45. Zorzi M, Frayle H, Rizzi M, et al; Veneto HPV-screening Working Group. A 3-year interval is too short for re-screening women testing negative for human papillomavirus: a population-based cohort study. BJOG. 2017;124(10):1585-1593.
46. Katki HA, Kinney WK, Fetterman B, et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. [published correction appears in Lancet Oncol. 2011;12(8):722]. Lancet Oncol. 2011;12(7):663-672.
47. Castle PE, Fetterman B, Poitras N, et al. Variable risk of cervical precancer and cancer after a human papillomavirus-positive test. Obstet Gynecol. 2011;117(3):650-656.
48. Gage JC, Katki HA, Schiffman M, et al. Age-stratified 5-year risks of cervical precancer among women with enrollment and newly detected HPV infection. Int J Cancer. 2015;136(7):1665-1671.
49. Gage JC, Schiffman M, Katki HA, et al. Reassurance against future risk of precancer and cancer conferred by a negative human papillomavirus test. J Natl Cancer Inst. 2014;106(8):dju153.
50. Katki HA, Schiffman M, Castle PE, et al. Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S56-S63.
51. Katki HA, Schiffman M, Castle PE, et al. Benchmarking CIN 3+ risk as the basis for incorporating HPV and Pap cotesting into cervical screening and management guidelines. J Low Genit Tract Dis. 2013;17(5)(suppl 1):S28-S35.
52. Ibáñez R, Autonell J, Sardà M, et al. Protecting the underscreened women in developed countries: the value of HPV test. BMC Cancer. 2014;14:574.
53. Demarco M, Lorey TS, Fetterman B, et al. Risks of CIN 2+, CIN 3+, and cancer by cytology and human papillomavirus status: the foundation of risk-based cervical screening guidelines. J Low Genit Tract Dis. 2017;21(4):261-267.
54. Dijkstra MG, van Zummeren M, Rozendaal L, et al. Safety of extending screening intervals beyond five years in cervical screening programmes with testing for high risk human papillomavirus: 14 year follow-up of population based randomised cohort in the Netherlands. BMJ. 2016;355:i4924.
55. Castle PE, Kinney WK, Xue X, et al. Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study. Ann Intern Med. 2018;168(1):20-29.
56. Coldman AJ, Gondara L, Smith LW, et al. Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial. Br J Cancer. 2016;115(12):1487-1494.
57. Cook DA, Mei W, Smith LW, et al. Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial. BMC Cancer. 2015;15:968.
58. Ogilvie GS, van Niekerk DJ, Krajden M, et al. A randomized controlled trial of human papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer. 2010;10:111.
59. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer. 2004;110(1):94-101.
60. Luyten A, Buttmann-Schweiger N, Luyten K, et al. Early detection of CIN3 and cervical cancer during long-term follow-up using HPV/Pap smear co-testing and risk-adapted follow-up in a locally organised screening programme. Int J Cancer. 2014;135(6):1408-1416.
61. Petry KU, Luyten A, Scherbring S. Accuracy of colposcopy management to detect CIN3 and invasive cancer in women with abnormal screening tests: results from a primary HPV screening project from 2006 to 2011 in Wolfsburg, Germany. Gynecol Oncol. 2013;128(2):282-287.
62. Dinkelspiel H, Fetterman B, Poitras N, et al. Screening history preceding a diagnosis of cervical cancer in women age 65 and older. Gynecol Oncol. 2012;126(2):203-206.
63. Fox J, Remington P, Layde P, Klein G. The effect of hysterectomy on the risk of an abnormal screening Papanicolaou test result. Am J Obstet Gynecol. 1999;180(5):1104-1109.
64. Pearce KF, Haefner HK, Sarwar SF, Nolan TE. Cytopathological findings on vaginal Papanicolaou smears after hysterectomy for benign gynecologic disease. N Engl J Med. 1996;335(21):1559-1562.
65. American Academy of Family Physicians (AAFP). Clinical preventive service recommendation: cervical cancer. AAFP website. https://www.aafp.org/patient-care/clinical-recommendations/all/cervical-cancer.html. 2018. Accessed June 28, 2018.
66. Committee on Practice Bulletins—Gynecology. Practice Bulletin No. 168: cervical cancer screening and prevention. Obstet Gynecol. 2016;128(4):e111-e130.
|Method||Frequency||Evidence of Efficacy||Other Considerations|
|Women Aged 21-29 y|
|Cytology||Every 3 y||Observational data23
|Screening with cytology is recommended in this age group
Screening with hrHPV testing is not recommended because of the transient nature of infection and natural clearance of HPV
|Women Aged 30-65 y|
|Cytology||Every 3 y||Observational data23
|Cytology has lower sensitivity than primary hrHPV testing or cotesting and a lower false-positive rate and rate of additional testing
The modeling study suggests that, compared with no screening, screening with cytology every 3 y can reduce the number of cervical cancer deaths from 8.34 to 0.76 deaths per 1000 womena
|Primary hrHPV testing||Every 5 y||4 RCTs of hrHPV testing vs cytology (screening intervals of 3.5 y,28,34 4 y,29,56-58 and 5 y30,31)
2 RCTs37,54 of cotesting, with 13-14 y of follow-up of HPV-negative component
1 US prospective cohort study53 of cotesting, with analysis of 5-y risk of death from HPV component
|Primary hrHPV testing has adequate sensitivity; see the Clinical Considerations section for triage protocols following a positive hrHPV test result
The modeling study suggests that, compared with no screening, switching from cytology to primary hrHPV testing every 5 y at age 30 y can reduce the number of cervical cancer deaths from 8.34 to 0.29 deaths per 1000 womena
|Cotesting||Every 5 y||4 RCTs of cotesting vs cytology (screening intervals of 3 y28,32,33,36-40,42 and 5 y41,54,59)
3 prospective cohort studies (United States,46-51 Spain,52 and Germany60,61)
|Cotesting may detect slightly more cases of CIN than screening with hrHPV testing alone but with a significant increase in the number of tests and procedures
The modeling study suggests that, compared with no screening, switching from cytology to cotesting every 5 y at age 30 y can reduce the number of cervical cancer deaths from 8.34 to 0.30 deaths per 1000 womena
aOutcomes calculated from models of cohorts of women aged 20 to 100 years; screening is assumed to end at age 65 years.
Abbreviations: CIN, cervical intraepithelial neoplasia; HPV, human papillomavirus; hrHPV, high-risk humanpapillomavirus; RCT, randomized clinical trial.